Stifel Bullish on Foghorn Therapeutics Stock
Stifel starts Foghorn Therapeutics coverage with Buy rating and $12 target. Lead drug FHD-909 partnership with Eli Lilly expected to launch in 2030 with strong sales potential.
/ 28 items
#LLY↓
Novo Nordisk Stock Plunges 10% as Ozempic Fails Alzheimer's Trial
Novo Nordisk shares tumbled 10% after Ozempic failed to slow Alzheimer's progression in clinical trials, marking another setback for the struggling Danish drugmaker against rival Eli Lilly.
LifeMD Shares Tumble on Earnings Miss and GLP-1 Market Struggles
LifeMD stock plunged 25% after missing Q3 earnings and cutting guidance, citing fierce competition from low-cost compounded GLP-1 weight loss drugs despite Novo and Lilly partnerships.
LifeMD Offers Lowest Cash-Pay Price for Wegovy & Ozempic at $199/Month
LifeMD now provides the lowest nationwide cash-pay price for Wegovy and Ozempic at $199/month for new patients, supporting more affordable access to GLP-1 weight-loss treatments.
Novo Nordisk, Eli Lilly Deny Mangoceuticals Partnership
Novo Nordisk and Eli Lilly reject Mangoceuticals' false partnership claims regarding weight-loss drugs.
Citi Boosts Eli Lilly Price Target to $1,500 on Strong Weight Loss Outlook
Citi raises Eli Lilly’s price target to $1,500, citing growing dominance in the weight loss market after a Medicare and Medicaid access deal and over $40B in potential peak sales.